Impact of Residual Disease on Disease Flares in Axial Spondyloarthritis: A Longitudinal Study in a Dutch Clinical Practice Registry
Abstract format and assignment number: Oral presentation OP0097
Date: Wednesday, 11 June, 16:30 – 16:40
Presenting author: E. Renet (Netherlands)
This retrospective study assessed whether the presence of residual disease in an inactive disease/ low disease activity state was associated with the occurrence of disease flares in the subsequent 12 months, using the data of 140 patients from the Dutch SpA-Net cohort. Patient-experienced residual disease was significantly associated with an increased hazard of flare, and shorter time-to-flare, compared to patients without patient-experienced residual disease in a multivariable analysis on the contrary to objective residual disease.
SYNOVIAL AND ENTHESIAL FIBROBLAST ACTIVATION DETECTED BY 68Ga-FAPI-04-PET/CT PREDICTS THE DEVELOPMENT OF PSORIATIC ARTHRITIS IN PATIENTS WITH PSORIASIS AND ARTHRALGIA
Abstract format and assignment number: Oral presentation OP174
Date: Thursday, 12 June, 10:30 – 10:40
Presenting author: G. Corte (Germany)
This prospective study assessed the association of increased fibroblast activation detected by 68Ga-FAPI-04 PET/CT with the onset of PsA in 44 PsO patients presenting with arthralgia. PsA developed in 18 patients, including 17/36 patients who had shown FAPI uptake at baseline as opposed to only 1/8 patients without FAPI uptake (HR 6.55, 95%CI 0.85-50.8). Despite not reaching statistical significance, patients who progressed to PsA had numerically higher mean cumulative SUVmax and PET-Joint Index than non-progressors.
IDENTIFICATION OF INFLAMMATORY AND NON-INFLAMMATORY MECHANISMS TO IMPROVE TREATMENT STRATEGIES IN DIFFICULT-TO-TREAT PSA PATIENTS USING CLINICAL AND SONOGRAPHIC FINDINGS
Abstract format and assignment number: Oral presentation OP0176
Date: Thursday, 12 June, 10:50 – 11:00
Presenting author: N. Cabbas (Italy)
In this multicenter, cross-sectional study with 53 difficult-to-treat PsA patients, those with persistent inflammatory PsA (PIPsA; n=30) had a higher median number of swollen joints, more frequently dactylitis and nail psoriasis, and more ultrasound activity and structural damages whereas those with non-inflammatory PsA (NIPsA; n=23) had a higher number of tender points and a greater median number of painful entheses.
DIFFERENCES IN STRUCTURAL LESIONS OF THE SPINE BETWEEN PATIENTS WITH EARLY axSpA AND NON-axSpA CHRONIC BACK PAIN: 2-YEAR RESULTS OF THE SPACE COHORT
Abstract format and assignment number: Oral presentation OP0310
Date: Friday, 13 June, 11:00 – 11:10
Presenting author: G. Ayan (Turkey)
This study aimed to compare structural lesions of the spine on coventional radiography (CR) and MRI over 2 years (2Y), as well as their 2Y-change, between patients with early axSpA and non-axSpA patients from the SPACE cohort. At 2Y, the axSpA group had significantly more fat lesions and total structural lesions compared to the non-axSpA group. Over 2Y, the progression of spinal structural lesions was similar between the axSpA and non-axSpA groups on CR, with overall mSASSS progression being minimal.
PREDICTORS OF SPINAL RADIOGRAPHIC PROGRESSION OVER UP TO 13 YEARS IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
Abstract format and assignment number: Oral presentation OP0314
Date: Friday, 13 June, 11:40 – 11:50
Presenting author: A. Deminger (Sweden)
This retrospective study aimed to examine spinal radiographic progression over 13 years and its predictors in patients with radiographic axial spondyloarthritis. There was a significant increase overall in mSASSS with a mean (SD) change in mSASSS of 1.6 (3.0) ( p < 0.001) from BL to 5-year follow-up (n=166) and 2.7 (4.3) (p < 0.001) from 5-year- to 13-year follow-up (n=126), resulting in a yearly average increase in mSASSS of 0.29 (0.55) and 0.34 (0.54) respectively.
Jean-Guillaume Letarouilly
Jean-Guillaume is a consultant rheumatologist at Lille University Hospital (France). His research interests include axial spondyloarthritis and psoriatic arthritis, the crosstalk with inflammatory bowel diseases and psoriasis, and difficult-to-treat axial spondyloarthritis and psoriatic arthritis.
He is a member of Young-GRAPPA and of the EMEUNET Visibility and Global Affairs Sub-committee.